Bionexus Gene Lab Stock Market Capitalization
| BGLC Stock | USD 6.47 0.46 6.64% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess BioNexus Gene's long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. BioNexus Gene Lab Company Market Capitalization Analysis
BioNexus Gene's Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current BioNexus Gene Market Capitalization | 11.62 M |
Most of BioNexus Gene's fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioNexus Gene Lab is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
| Competition |
Based on the recorded statements, the market capitalization of BioNexus Gene Lab is about 11.62 M. This is 99.91% lower than that of the Chemicals sector and 99.84% lower than that of the Materials industry. The market capitalization for all United States stocks is 99.94% higher than that of the company.
BioNexus Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioNexus Gene's direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioNexus Gene could also be used in its relative valuation, which is a method of valuing BioNexus Gene by comparing valuation metrics of similar companies.BioNexus Gene is currently under evaluation in market capitalization category among its peers.
BioNexus Fundamentals
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.23) % | ||||
| Operating Margin | (0.27) % | ||||
| Current Valuation | 8.34 M | ||||
| Shares Outstanding | 1.8 M | ||||
| Shares Owned By Insiders | 51.11 % | ||||
| Shares Owned By Institutions | 0.88 % | ||||
| Number Of Shares Shorted | 38.29 K | ||||
| Price To Earning | 350.00 X | ||||
| Price To Book | 1.51 X | ||||
| Price To Sales | 1.25 X | ||||
| Revenue | 9.51 M | ||||
| Gross Profit | 1.27 M | ||||
| EBITDA | (1.42 M) | ||||
| Net Income | (1.6 M) | ||||
| Cash And Equivalents | 1.34 M | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 210.56 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 3.84 X | ||||
| Book Value Per Share | 4.33 X | ||||
| Cash Flow From Operations | (2.23 M) | ||||
| Short Ratio | 0.01 X | ||||
| Earnings Per Share | (1.19) X | ||||
| Number Of Employees | 30 | ||||
| Beta | 1.81 | ||||
| Market Capitalization | 11.62 M | ||||
| Total Asset | 10.43 M | ||||
| Retained Earnings | (3.44 M) | ||||
| Working Capital | 5.48 M | ||||
| Net Asset | 10.43 M |
About BioNexus Gene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioNexus Gene Lab's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioNexus Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioNexus Gene Lab based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:Check out BioNexus Gene Piotroski F Score and BioNexus Gene Altman Z Score analysis. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.